title: Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine.
abstract: The results of a double-blind clinical trial of fengabine vs clomipramine in depressed outpatients are reported. Fengabine, a new GABAergic agent, seems to be as effective as the reference drug, with a faster onset of action and a more marked effect on cognitive disturbances and retardation. The new drug is free of any significant anticholinergic or cardiovascular effect, and it is not sedative.
authors.affiliation: Department of Mental Health, Consultative Psychiatric Services, Como, Italy.
authors.forename: N P
authors.initials: NP
authors.lastname: Nielsen
authors.forename: B
authors.initials: B
authors.lastname: Cesana
authors.forename: S
authors.initials: S
authors.lastname: Zizolfi
authors.forename: V
authors.initials: V
authors.lastname: Ascalone
authors.forename: P
authors.initials: P
authors.lastname: Priore
authors.forename: P L
authors.initials: PL
authors.lastname: Morselli
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002733:Chlorophenols / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
chemical_list: D000928:Antidepressive Agents; D002733:Chlorophenols; D002997:Clomipramine; C052028:fengabine